| Literature DB >> 30443000 |
Misako Nagatsuma1,2, Kei Takasawa3, Takeru Yamauchi4, Ryuichi Nakagawa4, Tomoko Mizuno4, Eriko Tanaka4, Kouhei Yamamoto5, Noriko Uemura6, Kenichi Kashimada4, Tomohiro Morio4.
Abstract
Schimmelpenning syndrome is a rare neurocutaneous disorder categorized as a mosaic RASopathy due to postzygotic HRAS or KRAS mutations. We report a 6-year-old girl diagnosed with Schimmelpenning syndrome due to a postzygotic KRAS G12D mutation. The patient had three atypical symptoms of Schimmelpenning syndrome: renovascular hypertension, congenital lipomatosis, and diabetes mellitus. The first two symptoms may overlap with phenotypes of other neurocutaneous syndromes or congenital lipomatous overgrowth syndrome due to mosaic RASopathies or other somatic mosaic mutations. We propose that impaired glucose tolerance was caused by KRAS mutation and a novel clinical phenotype of Schimmelpenning syndrome. Our study indicated that clinical diagnosis of Schimmelpenning syndrome or related conditions should be reorganized with genetic diagnosis of postzygotic mutation. Moreover, further accumulation of genetically proven cases with mosaic RASopathies should be used to more accurately characterize phenotypic presentations of this syndrome and develop a future therapeutic strategy, such as molecular-targeted therapy.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30443000 DOI: 10.1038/s10038-018-0539-3
Source DB: PubMed Journal: J Hum Genet ISSN: 1434-5161 Impact factor: 3.172